Ortin Laboratories (ORTINLAB) Stock Overview

Ortin Laboratories Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti-diabetics, anti allergics, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides; and anti-anginal and cardio vascular, and antifungal products. Its formulations also include chemo therapeutics, antacids and anti ulcerants, anti spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti retro viral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti ulcerants, and anti malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; and operates as a merchant exporter of pharmaceutical finished formulations. Ortin Laboratories Limited was incorporated in 1986 and is headquartered in Hyderabad, India.